STOCK TITAN
  1. Home
  2. News
  3. IRTC

iRhythm Technologies, Inc - IRTC STOCK NEWS

Welcome to our dedicated news page for iRhythm Technologies (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iRhythm Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iRhythm Technologies's position in the market.

News
iRhythm Technologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
iRhythm Technologies, Inc. (IRTC) to participate in 42nd Annual J.P. Morgan Healthcare Conference, with management presenting on January 8, 2024. The presentation will be available via live and archived webcast on the company's investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
conferences
-
News
Derrick Sung Joins Aerin Medical as Chief Financial Officer
Rhea-AI Summary
Aerin Medical Inc. appoints Derrick Sung as Chief Financial Officer. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, he was CFO at Pulmonx Corporation, leading the company through significant growth and a successful IPO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
-
News
New Research Presented at American Heart Association’s 2023 Scientific Sessions Demonstrates Performance of Continuous Monitoring ECG Data for Improved Prediction of Heart Failure Hospitalization
Rhea-AI Summary
iRhythm Technologies, Inc. (NASDAQ:IRTC) - Study findings from a collaboration with Duke Health revealed that incorporating ECG data from long-term continuous monitoring can more accurately predict heart failure hospitalization compared to clinical risk models. The data was presented at the American Heart Association’s 2023 Scientific Sessions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
News
iRhythm Technologies Announces Third Quarter 2023 Financial Results
Rhea-AI Summary
iRhythm Technologies, Inc. reported financial results for Q3 2023, with revenue of $124.6 million, a 20.0% increase compared to Q3 2022. Gross margin declined by 210 basis points. Cash, cash equivalents, and marketable securities were $158.5 million as of September 30, 2023. The company increased its fiscal year 2023 revenue guidance to a range of $487.5 million to $490 million. iRhythm achieved record registration volumes, launched the next generation Zio monitor, opened a Global Business Services center in the Philippines, and published cost-effectiveness data for mSToPs in Circulation: Cardiovascular Quality and Outcomes. Upcoming data presentations will be held at the American Heart Association (AHA) in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.2%
Tags
earnings
-
News
iRhythm Technologies to Report Third Quarter 2023 Financial Results on November 2, 2023
Rhea-AI Summary
iRhythm Technologies to release Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences earnings
-
News
iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor
Rhea-AI Summary
iRhythm launches next-generation Zio monitor in the U.S., with improved wear times and patient experience. Zio monitor demonstrates 99% patient compliance with prescribed wear times. The new monitor is 23% thinner, 62% lighter, 72% smaller, and weighs less than a pencil. iRhythm's AI algorithm is clinically proven to be as accurate as expert cardiologists. Zio LTCM service associated with highest diagnostic yield and lowest likelihood of retesting and hospitalization compared to other monitoring services. Zio monitor begins shipping now and will be widely available by early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
News
iRhythm Technologies to Participate in Two Investor Conferences in September
Rhea-AI Summary
iRhythm Technologies to present at Baird 2023 Global Healthcare Conference and Morgan Stanley 21st Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
conferences
-
News
Zio Granted High Medical Needs Designation by the Japanese Ministry of Health, Labour, and Welfare
Rhea-AI Summary
iRhythm's application for Zio Monitor System in Japan designated for high medical needs by the Ministry of Health, Labour, and Welfare. Positive clinical improvement and significant need for cardiac arrhythmia detection. Second largest ambulatory cardiac monitoring market in the world with 1.5 million tests prescribed annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.26%
Tags
none
-
News
iRhythm Technologies Announces Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.26%
Tags
earnings
News
iRhythm Technologies to Report Second Quarter 2023 Financial Results on August 3, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
conferences earnings
Stock IRTC logo
iRhythm Technologies, Inc

Nasdaq:IRTC

IRTC Rankings

#1428 Ranked by Market Cap
#4270 Ranked by Stock Gains
N/A Ranked by Dividends

IRTC Stock Data

3.48B
30.66M
1.05%
109.1%
8.24%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
San Francisco

About IRTC

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.